The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia
(AML) has resulted in a different paradigm for treatment compared with most other cancers …

Relapse after achieving a prior response remains one of the most important obstacles to
improving the outcome of patients with acute myeloid leukemia (AML). Although overall, the …

Abstract Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented
challenges for hematologists for decades. Despite numerous clinical studies, outcomes are …

The prognosis of relapsed acute myeloid leukaemia (AML) is poor and treatment is
challenging. While the most potent treatment modality for patients who achieve a complete …

Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Introduction: Acute myeloid leukemia [AML] is a heterogenous group of primary
hematopoietic neoplasms arising from myeloid precursor cells. Up to 50% of patients failed …

Relapsed/refractory AML is a heterogeneous disease and no uniform protocol will provide
cure to all patients. Molecular tests may contribute to future personalizing therapy resulting …

There are a significant number of patients diagnosed with acute leukemia who either fail to
achieve remission or who relapse thereafter. Challenges in treating this patient population …

Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Outcomes in patients treated for relapsed or refractory acute myeloid leukemia remain
inadequate. Striking a balance between the treatment-related mortality associated with …